Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
created: Sept. 23, 2025, 8:05 p.m. | updated: Sept. 24, 2025, 4:14 p.m.
Abivax Booth: For more information and to speak with Abivax representatives, visit the Abivax booth at the UEG exhibitor hall (Booth #4.25 in Hall 4.2).
Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements.
These forward-looking statements include statements concerning the Company’s expectations for the potential therapeutic benefit of obefazimod, and the Company’s participation at industry conferences.
Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release.
Readers are cautioned not to place undue reliance on these forward-looking statements.
1 month, 1 week ago: News Ticker - markets.businessinsider.com